Therefore, we aimed to examine feasibility and safety of nebulization of recombinant human tissue factor pathway inhibitor (rh-TFPI) in a well-established rat model of Streptococcus (S. ) pneumoniae pneumonia. This evidence concerns the gene TFPI and pneumonia.